FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes

December 23, 2024 -- Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic...